HIGHLIGHTS
- who: Randall J. Bateman from the Louis, MO, USA Department of Neurology, Washington University School of Medicine, St have published the research work: Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimeru2019s disease, in the Journal: (JOURNAL)
- what: This study demonstrated a dose-dependent reduction in PET Au03b2 plaque level after treatment with gantenerumab, laying the groundwork for clinical efficacy studies.
- how: Background This review describes the research and development process of gantenerumab a fully human antiamyloid monoclonal antibody in development to treat early symptomatic and asymptomatic Alzheimer . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.